Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Non-Current Deferred Tax Liability (2023 - 2025)

Cartesian Therapeutics (RNAC) has disclosed Non-Current Deferred Tax Liability for 3 consecutive years, with $6.9 million as the latest value for Q4 2025.

  • Quarterly Non-Current Deferred Tax Liability fell 83.87% to $6.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.9 million through Dec 2025, down 83.87% year-over-year, with the annual reading at $6.9 million for FY2025, 83.87% down from the prior year.
  • Non-Current Deferred Tax Liability for Q4 2025 was $6.9 million at Cartesian Therapeutics, down from $16.1 million in the prior quarter.
  • The five-year high for Non-Current Deferred Tax Liability was $44.0 million in Q4 2023, with the low at $6.9 million in Q4 2025.
  • Average Non-Current Deferred Tax Liability over 3 years is $21.1 million, with a median of $16.1 million recorded in 2025.
  • Peak annual rise in Non-Current Deferred Tax Liability hit 1.82% in 2025, while the deepest fall reached 83.87% in 2025.
  • Over 3 years, Non-Current Deferred Tax Liability stood at $44.0 million in 2023, then fell by 2.14% to $43.1 million in 2024, then crashed by 83.87% to $6.9 million in 2025.
  • According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods came in at $6.9 million, $16.1 million, and $16.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.